The authors note that prior studies have reported elevated levels of distress among people with cancer, but they vary in
quality due to small
sample sizes, different
diagnostic criteria and assessment standards, and an over-representation of women with breast cancer.
Potential risks and uncertainties include, but are not limited to, the risks: a) deCODE's previously discovered at - risk variants may not be sufficiently informative to have
diagnostic value; b) Illumina's BeadLab infrastructure may not support sufficiently the high
sample throughput envisioned by the parties; c) Illumina may not manufacture HumanHap BeadChips in adequate quantity or
quality; d) the companies may not see an increased customer base as a result of the collaboration, as well as other risks and uncertainties detailed from time to time in deCODE's or Illumina's filings with the Securities and Exchange Commission.